GKT 831

Drug Profile

GKT 831

Alternative Names: GKT-137831; GKT-831; UNII-45II35329V

Latest Information Update: 21 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GenKyoTex
  • Developer GenKyoTex; University of California, Davis; University of California, San Diego
  • Class Pyrazoles; Pyridines; Small molecules
  • Mechanism of Action NOX1 protein inhibitors; NOX4 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Idiopathic pulmonary fibrosis; Systemic scleroderma
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Diabetic nephropathies; Primary biliary cirrhosis
  • No development reported Hepatic fibrosis; Idiopathic pulmonary fibrosis; Non-alcoholic steatohepatitis; Systemic scleroderma
  • Discontinued Atherosclerosis; Bone disorders; Eye-Disorders

Most Recent Events

  • 28 Jun 2017 Genkyotex plans a phase II trial for Type 1 diabetes mellitus (associated with diabetic kidney disease) in Australia
  • 27 Jun 2017 Phase-II clinical trials in Primary biliary cirrhosis in USA (PO)
  • 05 May 2017 Discontinued - Preclinical for Atherosclerosis in Switzerland (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top